Quick Answer
Dyne Therapeutics, Inc. reported Operating Income of -$468.18 million for fiscal year 2025.
Dyne Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$468.18M | -36.1% |
| 2024 | -$343.89M | -42.0% |
| 2023 | -$242.16M | -41.6% |
| 2022 | -$170.96M | -14.0% |
| 2021 | -$150.03M | -155.8% |
| 2020 | -$58.65M | -324.2% |
| 2019 | -$13.83M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$113.89M | -7.9% | +1.6% |
| June 30, 2025 | -$115.79M | -60.9% | +5.4% |
| March 31, 2025 | -$122.37M | -76.9% | -15.9% |
| September 30, 2024 | -$105.57M | -69.5% | -46.7% |
| June 30, 2024 | -$71.96M | -7.8% | -4.1% |
| March 31, 2024 | -$69.16M | -52.1% | -11.1% |
| September 30, 2023 | -$62.27M | -47.3% | +6.7% |
| June 30, 2023 | -$66.74M | -26.5% | -46.8% |
- Dyne Therapeutics, Inc. showed a decrease of -36.1% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, Dyne Therapeutics, Inc.’s operating income has declined by 3286.3% (from -$13.83 million to -$468.18 million).
- The most recent figure is from Dyne Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: